Abstract
During the past few years, Epithelial-Mesenchymal Transition (EMT) has emerged as one of the most hot spots in clinical research. Its existence in human tumors can form the basis for explaining characteristics of cancer progression and metastasis, as well as certain cases of drug resistance and relapses after treatment. These cellular responses are tightly regulated by intracellular signaling pathways evoked by humoral factors that include growth factors, chemokines and cytokines. Indeed, several gene regulatory programs known to promote EMT during development have recently been discovered to play key roles in cancer progression. A deeper understanding of the cellular and molecular basis of these different programs should aid in both the development of better diagnosis methods, as well as of specific treatments for invasive cancer. In this review we set out to summarize recent novel insights into the molecular players underlying EMT and its relation with cancer progression and metastasis.
Keywords: Cancer, EMT, invasion, metastasis, MMP, NF-B, RTKs, TGF-, humoral factors, molecular players underlying EMT, epithelial cells phenotype, epithelial genes, cell-matrix interactions, pathological processes, cell surface E-cadherin
Current Pharmaceutical Biotechnology
Title: Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis
Volume: 12 Issue: 11
Author(s): L. R. Gomes, L. F. Terra, M. C. Sogayar and L. Labriola
Affiliation:
Keywords: Cancer, EMT, invasion, metastasis, MMP, NF-B, RTKs, TGF-, humoral factors, molecular players underlying EMT, epithelial cells phenotype, epithelial genes, cell-matrix interactions, pathological processes, cell surface E-cadherin
Abstract: During the past few years, Epithelial-Mesenchymal Transition (EMT) has emerged as one of the most hot spots in clinical research. Its existence in human tumors can form the basis for explaining characteristics of cancer progression and metastasis, as well as certain cases of drug resistance and relapses after treatment. These cellular responses are tightly regulated by intracellular signaling pathways evoked by humoral factors that include growth factors, chemokines and cytokines. Indeed, several gene regulatory programs known to promote EMT during development have recently been discovered to play key roles in cancer progression. A deeper understanding of the cellular and molecular basis of these different programs should aid in both the development of better diagnosis methods, as well as of specific treatments for invasive cancer. In this review we set out to summarize recent novel insights into the molecular players underlying EMT and its relation with cancer progression and metastasis.
Export Options
About this article
Cite this article as:
R. Gomes L., F. Terra L., C. Sogayar M. and Labriola L., Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis, Current Pharmaceutical Biotechnology 2011; 12(11) . https://dx.doi.org/10.2174/138920111798377102
DOI https://dx.doi.org/10.2174/138920111798377102 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview
Anti-Cancer Agents in Medicinal Chemistry Hepatoma-Derived Growth Factor in Carcinogenesis and Cancer Progression
Current Drug Therapy State-of-the-Art Methodologies for the Discovery and Characterization of DNA G-Quadruplex Binders
Current Pharmaceutical Design Anticancer Antioxidant Regulatory Functions of Phytochemicals
Current Medicinal Chemistry Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Vascular Endothelial Growth Factor in Central Nervous System Injuries – A Vascular Growth Factor Getting Nervous?
Current Neurovascular Research Germacrone: A Potent Secondary Metabolite with Therapeutic Potential in Metabolic Diseases, Cancer and Viral Infections
Current Drug Metabolism Comparative Genomic Hybridization: A Valuable Tool for Genome-Scale Analysis of Rodent Cancer Models
Current Genomics Stem Cells as In Vitro Models of Disease
Current Stem Cell Research & Therapy Attention Deficit Hyperactivity Disorder and N-methyl-D-aspartate (NMDA) Dysregulation
Current Pharmaceutical Design Design, Synthesis and Anticancer Activity Evaluation of Diazepinomicin Derivatives
Letters in Drug Design & Discovery Artemisia Species as a New Candidate for Diabetes Therapy: A Comprehensive Review
Current Molecular Medicine MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Current Molecular Medicine Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry Brain Tumor Detection and Classification by Hybrid CNN-DWA Model Using MR Images
Current Medical Imaging Cyclooxygenase-2: Potential Role in Regulation of Drug Efflux and Multidrug Resistance Phenotype
Current Pharmaceutical Design Current Application of Quantum Dots (QD) in Cancer Therapy: A Review
Mini-Reviews in Medicinal Chemistry Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions
Current Medicinal Chemistry